Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$45.24 USD

45.24
2,220,733

-0.61 (-1.33%)

Updated Aug 6, 2025 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

Zacks Equity Research

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

by Zacks Equity Research

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

Zacks Equity Research

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

by Zacks Equity Research

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

by Zacks Equity Research

Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.

Sundeep Ganoria headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

by Sundeep Ganoria

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

Zacks Equity Research

All You Need to Know About Bristol Myers (BMY) Rating Upgrade to Buy

by Zacks Equity Research

Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Zacks Equity Research

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

by Zacks Equity Research

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Zacks Equity Research

Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results

by Zacks Equity Research

Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.

Ekta Bagri headshot

Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?

by Ekta Bagri

Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.

Zacks Equity Research

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

by Zacks Equity Research

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Zacks Equity Research

Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Ekta Bagri headshot

Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback

by Ekta Bagri

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.

Zacks Equity Research

BMY vs. VRTX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.

Zacks Equity Research

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Company News for Jul 29, 2024

by Zacks Equity Research

Companies in The News Are: NSC, CHTR, CL, BMY

Zacks Equity Research

PCE/Core PCE Inflation In Line With Estimates in June

by Zacks Equity Research

PCE/Core PCE Inflation In Line With Estimates in June.

Mark Vickery headshot

Pre-Markets Swell, PCE Behaves, Several Q2 Beats

by Mark Vickery

Pre-market futures are jumping this morning, though this may have to do with favorable market conditions after the sell-off mid-week.

Zacks Equity Research

Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View

by Zacks Equity Research

Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.

Zacks Equity Research

Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 26.22% and 5.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

DECK, SKX Higher After Earnings; PCE On Tap Friday

by Mark Vickery

The maker of Hoka footwear, UGG boots and more, posted a giant beat on its fiscal Q1 bottom line.